Trikafta and Nasal dryness - a phase IV clinical study of FDA data

Summary:

Nasal dryness is reported as a side effect among people who take Trikafta (elexacaftor, ivacaftor, tezacaftor; ivacaftor), especially for people who are female, 30-39 old, have been taking the drug for < 1 month also take Creon, and have Cystic fibrosis.

The phase IV clinical study analyzes which people have Nasal dryness when taking Trikafta. It is created by eHealthMe based on reports of 11,845 people who have side effects when taking Trikafta from the FDA, and is updated regularly.

What is Trikafta?

Trikafta has active ingredients of elexacaftor, ivacaftor, tezacaftor; ivacaftor. eHealthMe is studying from 11,852 Trikafta users. Check the latest studies of Trikafta.

What is Nasal dryness?

Nasal dryness (dry nose) is found to be associated with 647 drugs and 661 conditions by eHealthMe. Check the latest studies of Nasal dryness.

On Jul, 04, 2026

11,845 people reported to have side effects when taking Trikafta.
Among them, 16 people (0.14%) have Nasal dryness.

Among these 16 people:

How long have people been on Trikafta when they have Nasal dryness? *

What is the gender of people who have Nasal dryness when taking Trikafta? *

female: 68.75 %
male: 31.25 %

What is the age of people who have Nasal dryness when taking Trikafta? *

What are other drugs people take besides Trikafta? *

What are other side effects people have besides Nasal dryness? *

Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 8 people, 50.00%
Nasal Discomfort: 7 people, 43.75%
Chest Pain: 5 people, 31.25%
Fatigue (feeling of tiredness): 5 people, 31.25%
Weakness: 5 people, 31.25%
Respiratory Syncytial Virus Infection (viral disease of respiratory system): 5 people, 31.25%
Nosebleed (bleeding from nose): 5 people, 31.25%
Pulmonary Function Test Decreased: 4 people, 25.00%
Weight Increased: 3 people, 18.75%
Premature Delivery: 3 people, 18.75%

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 15 people, 93.75%
Nosebleed (bleeding from nose): 2 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Trikafta and have Nasal dryness?

- Check whether Nasal dryness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Trikafta:

Trikafta (11,852 reports)

Nasal dryness treatments and more:

Nasal dryness (8,014 reports)

How severe was Nasal dryness and when was it recovered:

Nasal dryness in Trikafta

Expand to all the drugs that have ingredients of elexacaftor, ivacaftor, tezacaftor; ivacaftor:

Nasal dryness and drugs with ingredients of elexacaftor, ivacaftor, tezacaftor; ivacaftor

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Trikafta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nasal dryness:

Nasal dryness (647 drugs)

Browse all the conditions that are associated with Nasal dryness:

Nasal dryness (661 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on elexacaftor, ivacaftor, tezacaftor; ivacaftor (the active ingredients of Trikafta) and Trikafta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.